{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:04Z","timestamp":1767485764132,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502701)"],"award-info":[{"award-number":["2022YFC2502701)"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470166"],"award-info":[{"award-number":["82470166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06658-7","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:58:33Z","timestamp":1763362713000},"page":"6467-6471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy based on venetoclax overcomes resistance to all-trans retinoic acid and arsenic trioxide in a variant acute promyelocytic leukemia with TNRC18::RARA fusion"],"prefix":"10.1007","volume":"104","author":[{"given":"Wenjing","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"6658_CR1","doi-asserted-by":"crossref","unstructured":"Liu M, Zhao X, Pan W et al (2021) A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML\u2010RARA rearrangement, sensitive to venetoclax\u2010based therapy. Br J Haematol. ;195(2)","DOI":"10.1111\/bjh.17642"},{"key":"6658_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828852","volume":"12","author":"B Song","year":"2022","unstructured":"Song B, Wang X, Kong X (2022) Clinical response to venetoclax and decitabine in acute promyelocytic leukemia with a novel RARA-THRAP3 fusion: a case report. Front Oncol 12:828852","journal-title":"Front Oncol"},{"issue":"17","key":"6658_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020619","volume":"142","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Li H, Chen X (2023) Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia. Blood 142(17):6","journal-title":"Blood"},{"key":"6658_CR4","doi-asserted-by":"publisher","first-page":"1028651","DOI":"10.3389\/fonc.2022.1028651","volume":"12","author":"W Ding","year":"2023","unstructured":"Ding W, Weng G, Wang Z et al (2023) Case report: identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement. Front Oncol 12:1028651\u20131028651","journal-title":"Front Oncol"},{"issue":"5","key":"6658_CR5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjh.18476","volume":"199","author":"H Li","year":"2022","unstructured":"Li H, Xiang X, Ding H et al (2022) Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA. Br J Haematol 199(5):768\u2013771","journal-title":"Br J Haematol"},{"issue":"2","key":"6658_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000111","volume":"4","author":"G Zhang","year":"2022","unstructured":"Zhang G, Song Y, Wan L et al (2022) Treatment of STAT5b-RARA positive acute promyelocytic leukemia by venetoclax combining with homoharringtonine, cytarabine: a case report and literature review. Blood Sci 4(2):4","journal-title":"Blood Sci"},{"issue":"4","key":"6658_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/mc.23671","volume":"63","author":"J Xu","year":"2024","unstructured":"Xu J, Li H, Wang Z et al (2024) Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion. Mol Carcinog 63(4):553\u2013557","journal-title":"Mol Carcinog"},{"issue":"12","key":"6658_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pbc.30665","volume":"70","author":"J Chen","year":"2023","unstructured":"Chen J, Zhou X, Chen X et al (2023) Pediatric TTMV::RARA-positive relapsed acute promyelocytie leukemia responsive to venetoclax and achieving long remission after allogenic transplantation. Pediatr Blood Cancer 70(12):4","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"6658_CR9","doi-asserted-by":"publisher","first-page":"E48","DOI":"10.1002\/ajh.25689","volume":"95","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Jiang M, Borthakur G (2020) Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to Homoharringtonine and cytarabine chemotherapy. Am J Hematol 95(2):E48\u2013E51","journal-title":"Am J Hematol"},{"issue":"13","key":"6658_CR10","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1182\/bloodadvances.2022008364","volume":"7","author":"H-H Zhu","year":"2023","unstructured":"Zhu H-H, Qin Y-Z, Zhang Z-L (2023) A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv 7(13):2972\u20132982","journal-title":"Blood Adv"},{"issue":"14","key":"6658_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1182\/blood.2024023883","volume":"144","author":"X Zhou","year":"2024","unstructured":"Zhou X, Chen X, Chen J et al (2024) Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL. Blood 144(14):1471\u20131485","journal-title":"Blood"},{"issue":"4","key":"6658_CR12","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.3324\/haematol.2018.209478","volume":"104","author":"R Abboud","year":"2019","unstructured":"Abboud R, Han SY, Duncavage EJ et al (2019) Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. Haematologica 104(4):e170","journal-title":"Haematologica"},{"issue":"1","key":"6658_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/16078454.2022.2066825","volume":"27","author":"Y Song","year":"2022","unstructured":"Song Y, Hou J, Wan L et al (2022) A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia. Hematology 27(1):518\u2013522","journal-title":"Hematology"},{"issue":"1","key":"6658_CR14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41467-022-29336-y","volume":"13","author":"T Liu","year":"2022","unstructured":"Liu T, Rao J, Hu W et al (2022) Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification. Nat Commun 13(1):1640","journal-title":"Nat Commun"},{"issue":"6","key":"6658_CR15","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2010-04-277434","volume":"117","author":"P Montesinos","year":"2011","unstructured":"Montesinos P, Ray\u00f3n C, Vellenga E et al (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117(6):1799\u20131805","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06658-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:08Z","timestamp":1767485708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06658-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6658"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06658-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the First Affiliated Hospital of Soochow University, Suzhou, China(2024-607). U937 cell and 32D cell come from the Jiangsu Institute of Hematology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}